Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + pirtobrutinib + methotrexate + dexamethasone + thiotepa
- Development stage
- Unknown
- Lead developer
- Zou Dehui
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
R-PMDT is an investigational chemoimmunotherapy combination regimen designed for the treatment of newly diagnosed primary central nervous system lymphoma (PCNSL). The regimen integrates five therapeutic agents: rituximab (an anti-CD20 monoclonal antibody), pirtobrutinib (a highly selective, non-covalent Bruton's tyrosine kinase inhibitor), high-dose methotrexate (an antimetabolite), dexamethasone (a corticosteroid), and thiotepa (an alkylating agent). This combination is specifically structured to leverage agents with known efficacy in B-cell malignancies and the ability to penetrate the blood-brain barrier, aiming to improve the overall response rate and survival outcomes in patients with PCNSL.
- Other names
- R-PMDT regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)DNABTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on rituximab + pirtobrutinib + methotrexate + dexamethasone + thiotepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + pirtobrutinib + methotrexate + dexamethasone + thiotepa.